Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT/CD155 pathway

References

• Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(11):1399–1420. DOI:10.1002/ajh.25950
   PubMed Web of Science ®Google Scholar
• Raza A, Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer. 2012;12(12):849–859. DOI:10.1038/nrc3321
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088. DOI:10.1182/blood.V89.6.2079
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465. DOI:10.1182/blood-2012-03-420489
   PubMed Web of Science ®Google Scholar
• Safarzadeh E, Orangi M, Mohammadi H, et al. Myeloid-derived suppressor cells: important contributors to tumor progression and metastasis. J Cell Physiol. 2018;233(4):3024–3036. DOI:10.1002/jcp.26075
   PubMed Web of Science ®Google Scholar
• Bronte V, Brandau S, Chen S-H, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150. DOI:10.1038/ncomms12150
   PubMed Web of Science ®Google Scholar
• Damuzzo V, Pinton L, Desantis G, et al. Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom. 2015;88(2):77–91. DOI:10.1002/cyto.b.21206
   PubMed Web of Science ®Google Scholar
• Mandruzzato S, Brandau S, Britten CM, et al. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunol Immunother. 2016;65(2):161–169. DOI:10.1007/s00262-015-1782-5
   PubMed Web of Science ®Google Scholar
• Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461–469. DOI:10.1182/blood-2007-09-077438
   PubMed Web of Science ®Google Scholar
• Meng F, Li L, Lu F, et al. Overexpression of TIGIT in NK and T cells contributes to tumor immune escape in myelodysplastic syndromes. Front Oncol. 2020;10:1595. DOI:10.3389/fonc.2020.01595
   PubMed Web of Science ®Google Scholar
• Liu Z, Guo Y, Huang L, et al. Bone marrow mesenchymal stem cells regulate the dysfunction of NK cells via the T cell immunoglobulin and ITIM domain in patients with myelodysplastic syndromes. Cell Commun Signal. 2022;20(1):169. DOI:10.1186/s12964-022-00985-2
   PubMed Web of Science ®Google Scholar
• Manieri NA, Chiang EY, Grogan JL. TIGIT: a key inhibitor of the cancer immunity cycle. Trends Immunol. 2017;38(1):20–28. DOI:10.1016/j.it.2016.10.002
   PubMed Web of Science ®Google Scholar
• Sarhan D, Cichocki F, Zhang B, et al. Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells. Cancer Res. 2016;76(19):5696–5706. DOI:10.1158/0008-5472.CAN-16-0839
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. DOI:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44–49. DOI:10.1126/science.1198687
   PubMed Web of Science ®Google Scholar
• Xu SJ, Shao ZH, Fu R, et al. [Subtype and functional biomarker changes of NK cells in peripheral blood of patients with myelodysplastic syndrome]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017;25(3):832–836.
   PubMedGoogle Scholar
• Mi H, Fu R, Wang H, et al. [Changes of natural kill cell in peripheral blood of patients with myelodysplastic syndrome]. Zhonghua Yi Xue Za Zhi. 2014;94(10):737–741.
   PubMedGoogle Scholar
• Hoechst B, Voigtlaender T, Ormandy L, et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology. 2009;50(3):799–807. DOI:10.1002/hep.23054
   PubMed Web of Science ®Google Scholar
• Stiff A, Trikha P, Mundy-Bosse B, et al. Nitric oxide production by myeloid-derived suppressor cells plays a role in impairing Fc receptor-mediated natural killer cell function. Clin Cancer Res. 2018;24(8):1891–1904. DOI:10.1158/1078-0432.CCR-17-0691
   PubMed Web of Science ®Google Scholar
• Vaknin I, Blinder L, Wang L, et al. A common pathway mediated through toll-like receptors leads to T- and natural killer-cell immunosuppression. Blood. 2008;111(3):1437–1447. DOI:10.1182/blood-2007-07-100404
   PubMed Web of Science ®Google Scholar
• Li H, Han Y, Guo Q, et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009;182(1):240–249. DOI:10.4049/jimmunol.182.1.240
   PubMed Web of Science ®Google Scholar
• Kittang AO, Kordasti S, Sand KE, et al. Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. Oncoimmunology. 2016;5(2):e1062208. DOI:10.1080/2162402X.2015.1062208
   PubMed Web of Science ®Google Scholar
• Cheng P, Corzo CA, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008;205(10):2235–2249. DOI:10.1084/jem.20080132
   PubMed Web of Science ®Google Scholar
• Sinha P, Okoro C, Foell D, et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008;181(7):4666–4675. DOI:10.4049/jimmunol.181.7.4666
   PubMed Web of Science ®Google Scholar
• Chen X, Eksioglu EA, Zhou J, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest. 2013;123(11):4595–4611. DOI:10.1172/JCI67580
   PubMed Web of Science ®Google Scholar
• Schneider RK, Schenone M, Ferreira MV, et al. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med. 2016;22(3):288–297. DOI:10.1038/nm.4047
   PubMed Web of Science ®Google Scholar
• Basiorka AA, McGraw KL, Eksioglu EA, et al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016;128(25):2960–2975. DOI:10.1182/blood-2016-07-730556
   PubMed Web of Science ®Google Scholar
• Zhang J, Han X, Hu X, et al. IDO1 impairs NK cell cytotoxicity by decreasing NKG2D/NKG2DLs via promoting miR-18a. Mol Immunol. 2018;103:144–155. DOI:10.1016/j.molimm.2018.09.011
   PubMed Web of Science ®Google Scholar
• Santini V. How I treat MDS after hypomethylating agent failure. Blood. 2019;133(6):521–529. DOI:10.1182/blood-2018-03-785915
   PubMed Web of Science ®Google Scholar
• Kong Y, Zhu L, Schell TD, et al. T-Cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients. Clin Cancer Res. 2016;22(12):3057–3066. DOI:10.1158/1078-0432.CCR-15-2626
   PubMed Web of Science ®Google Scholar